AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies

AbbVie and Xilio Therapeutics entered a collaboration and option-to-license agreement to develop tumor-activated immunotherapies, including masked T cell engagers12.

Xilio will receive $52 million in upfront payments, including a $10 million equity investment from AbbVie58.

The deal includes potential additional payments of up to $2.1 billion in option-related fees, milestones, and tiered royalties25.

The collaboration leverages Xilio's proprietary tumor-activation technology platform to develop novel antibody-based immunotherapies35.

Xilio is advancing three wholly-owned preclinical programs for masked T cell engagers targeting PSMA, CLDN18.2, and STEAP119.

The partnership aims to improve tolerability and reduce toxicity of cancer treatments through tumor-selective activation of immunotherapies9.

Xilio's cash runway is expected to extend into the first quarter of 2026 as a result of this collaboration89.

The agreement combines AbbVie's oncology expertise with Xilio's tumor-activation technology to develop next-generation cancer treatments35.

Sources:

1. https://synapse.patsnap.com/organization/d18a06ec02eaae37aa17aae3572fc168

2. https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-multiple-masked-t-cell-engager

3. https://www.pharmaceutical-technology.com/news/abbvie-xilio-immunotherapies/

5. https://www.prnewswire.com/news-releases/abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement-to-develop-novel-tumor-activated-immunotherapies-302371535.html

8. https://www.morningstar.com/news/dow-jones/202502127610/abbvie-xilio-therapeutics-set-collaboration-option-to-license-agreement

9. https://www.nasdaq.com/articles/xilio-therapeutics-announces-collaboration-abbvie-advance-novel-tumor-activated